

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/772,089	02/05/2004	Michael R. Farzan	7570/80968	4152
66991 7590 05/28/2008 LAW OFFICE OF MICHAEL A. SANZO, LLC			EXAMINER	
15400 CALHOUN DR. SUITE 125 ROCKVILLE, MD 20855			PARKIN, JEFFREY S	
			ART UNIT	PAPER NUMBER
noen index,	1115 20005		1648	•
			MAIL DATE	DELIVERY MODE
			05/28/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/772.089 FARZAN ET AL. Office Action Summary Examiner Art Unit Jeffrey S. Parkin, Ph.D. 1648

The MAILING DATE of this communication appear Period for Reply	s on the cover sheet with the correspondence address				
WHICHEVER IS LONGER, FROM THE MAILING DATE - Extensions of time may be available under the provisions of 37 CFR 1.136(a) after SIX (6) MONTHS from the mailing date of this communication.	 In no event, however, may a reply be timely filed oply and will expire SIX (6) MONTHS from the mailing date of this communication. se the application to become ABANDONED (35 U.S.C. § 133). 				
Status					
1) Responsive to communication(s) filed on 02 Janua	ary 2008.				
2a) ☐ This action is FINAL. 2b) ☐ This act	tion is non-final.				
3) Since this application is in condition for allowance	except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex p	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4)⊠ Claim(s) 60-75 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn to	rom consideration.				
5)⊠ Claim(s) <u>60-74</u> is/are allowed.					
6)⊠ Claim(s) <u>75</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or ele	ection requirement.				
Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on 02 January, 2008, is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the draw	wing(s) be held in abeyance. See 37 CFR 1.85(a).				
	is required if the drawing(s) is objected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the Exam	iner. Note the attached Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign price a) All b) Some * c) None of:	ority under 35 U.S.C. § 119(a)-(d) or (f).				
 Certified copies of the priority documents have 	ave been received.				
Certified copies of the priority documents have					
	documents have been received in this National Stage				
application from the International Bureau (P					
* See the attached detailed Office action for a list of t	ne certined copies not received.				
Attachment(s)					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (PTO-413) Paper No(s)/Mail Date.				

5) Notice of Informal Patent Application.
6) Other: 3) Information Disclosure Statement(s) (PTC/S5/08) Paper No(s)/Mail Date _____.

 Serial No.: 10/772,089
 Docket No.: 7570/80968

 Applicants: Farzan, M. R., et al.
 Filing Date: 02/05/2004

Detailed Office Action

Status of the Claims

Acknowledgement is hereby made of receipt and entry of the communication filed 02 January, 2008. Claims 1, 2, and 40-59 were canceled without prejudice or disclaimer and new claims 60-75 submitted.

Claim Objections

The previous objection to claims 1, 2, 49-51, and 58 is moot in view of applicants' amendment canceling these claims.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. \S 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Scope of Enablement

The previous rejection of claims 1, 2, 49-51, and 58 under 35 U.S.C. § 112, first paragraph, because the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims, is moot in view of applicants' amendment canceling these claims.

Serial No.: 10/772,089 Applicants: Farzan, M. R., et al.

Allowable Subject Matter

Claims 60-74 appear to be free of the prior art and are allowable. The original restriction requirement between the product (a peptide comprising SEQ ID NO.: 4) and method of use has been rescinded and claim 75 rejoined.

35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. \S 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 75 is rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Two separate requirements are set forth under this statute: (1) the claims must set forth the subject matter that applicants regard as their invention; and (2) the claims must particularly point out and distinctly define the metes and bounds of the subject matter that will be protected by the patent grant. The claim is incomplete for omitting essential steps, such omission amounting to a gap between the steps. See M.P.E.P. § 2172.01. Attempts to claim a process without setting forth a sufficient number of steps involved in the process generally raises an issue of indefiniteness under 35 U.S.C. § 112, second paragraph. For example, a claim which read: "A process for using monoclonal antibodies of claim 4 to isolate and purify human fibroblast interferon." was held to be indefinite because it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Serial No.: 10/772,089 Applicants: Farzan, M. R., et al.

Ex parte Erlich, 3 U.S.P.Q.2d 1011 (Bd. Pat. App. & Inter. 1986). In the instant scenario, the claim simply includes a contact step. However, it fails to adequately set forth the salient characteristics of the claimed invention (i.e., sample preparation; administration step specifying the target and route administration: determination οf ٥f some meaningful virological/clinical parameter that demonstrates that the peptides were effective; etc.). Applicants' representative is invited to contact the examiner to discuss suggested revisions to the claim language.

Action Is Final, Necessitated by Amendment

Applicant's amendment necessitated the new ground(s) rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See M.P.E.P. § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 C.F.R. § 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571)

Serial No.: 10/772,089 Applicants: Farzan, M. R., et al.

272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

/Jeffrey S. Parkin, Ph.D./ Primary Examiner, Art Unit 1648

22 May, 2008